Skip to main navigation Skip to search Skip to main content

Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus

  • Ines C. Kanter
  • , Hagen B. Huttner
  • , Dimitre Staykov
  • , Teresa Biermann
  • , Tobias Struffert
  • , Frank Kerling
  • , Max Josef Hilz
  • , Peter D. Schellinger
  • , Stefan Schwab
  • , Jürgen Bardutzky

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Abstract

Glutamic acid decarboxylase (GAD) is the enzyme which catalyzes the production of gamma aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system (CNS). There is increasing evidence that severe GAD autoimmunity may be associated with refractory epilepsy. Immunomodulation and GABAergic drugs have been suggested as treatment options. We report here for the first time on a patient with sudden onset of refractory status epilepticus in the presence of strong intrathecal anti-GAD antibody synthesis who was successfully treated with cyclophosphamide, and give an overview of available data on epilepsy associated with GAD autoimmunity.

Original languageEnglish
Pages (from-to)914-920
Number of pages7
JournalEpilepsia
Volume49
Issue number5
DOIs
StatePublished - May 2008
Externally publishedYes

Keywords

  • Anti-GAD antibodies
  • Cyclophosphamide
  • Epilepsy
  • Intrathecal GAD-Ab synthesis

Fingerprint

Dive into the research topics of 'Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus'. Together they form a unique fingerprint.

Cite this